Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate whether hydrodistention with fulguration of Hunner lesions (HD/FUL) plus maintenance dimethyl sulfoxide (DMSO) therapy prolongs the recurrence-free time in patients with Hunner type interstitial cystitis (IC). Methods: The study enrolled patients with Hunner type IC who required repeat HD/FUL due to recurrence of IC symptoms after the first HD/FUL at our institution. All patients received a second HD/FUL plus maintenance DMSO therapy. The maintenance DMSO therapy was performed every 2 weeks for a total of 8 instillations, and then once every 4 weeks thereafter. The recurrencefree time from HD/FUL to therapeutic failure was estimated using the Kaplan-Meier method. The recurrence-free time between the first HD/FUL and second HD/FUL plus maintenance DMSO therapy was statistically compared using the log-rank test. Results: A total of 21 patients (mean age, 66.3±10.8 years) with Hunner type IC were evaluated. The recurrence-free time for the second HD/FUL plus maintenance DMSO therapy was significantly longer than that for the first HD/FUL (P<0.0001). The median recurrence-free time for the first HD/FUL was 10.1 months, while that for the second HD/FUL plus maintenance DMSO therapy has yet to be reached. The recurrence-free rate for the first HD/FUL was 81.0% at 6 months, 38.1% at 1 year, 9.5% at 2 years, and 4.8% at 3 years. In contrast, the rate for the second HD/FUL plus maintenance DMSO therapy was 100% at 6 months, 94.7% at 1 year, 82.6% at 2 years, and 82.6% at 3 years. There were no significant differences in efficacy between the first and second HD/FUL. Conclusions: HD/FUL plus maintenance DMSO therapy clearly prolongs the recurrence-free time compared with HD/FUL alone in Hunner type IC.
Abstract
Purpose: To evaluate whether hydrodistention with fulguration of Hunner lesions (HD/FUL) plus maintenance dimethyl sulfoxide (DMSO) therapy prolongs the recurrence-free time in patients with Hunner type interstitial cystitis (IC). Methods: The study enrolled patients with Hunner type IC who required repeat HD/FUL due to recurrence of IC symptoms after the first HD/FUL at our institution. All patients received a second HD/FUL plus maintenance DMSO therapy. The maintenance DMSO therapy was performed every 2 weeks for a total of 8 instillations, and then once every 4 weeks thereafter. The recurrencefree time from HD/FUL to therapeutic failure was estimated using the Kaplan-Meier method. The recurrence-free time between the first HD/FUL and second HD/FUL plus maintenance DMSO therapy was statistically compared using the log-rank test. Results: A total of 21 patients (mean age, 66.3±10.8 years) with Hunner type IC were evaluated. The recurrence-free time for the second HD/FUL plus maintenance DMSO therapy was significantly longer than that for the first HD/FUL (P<0.0001). The median recurrence-free time for the first HD/FUL was 10.1 months, while that for the second HD/FUL plus maintenance DMSO therapy has yet to be reached. The recurrence-free rate for the first HD/FUL was 81.0% at 6 months, 38.1% at 1 year, 9.5% at 2 years, and 4.8% at 3 years. In contrast, the rate for the second HD/FUL plus maintenance DMSO therapy was 100% at 6 months, 94.7% at 1 year, 82.6% at 2 years, and 82.6% at 3 years. There were no significant differences in efficacy between the first and second HD/FUL. Conclusions: HD/FUL plus maintenance DMSO therapy clearly prolongs the recurrence-free time compared with HD/FUL alone in Hunner type IC.
참고문헌 (23)
- Homma Y, "Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015", Int J Urol, 23, pp.542~549 (2016)
- Glemain P, "Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis : efficacy at 6 months and 1 year", Eur Urol, 41, pp.79~84 (2002)
- Ottem DP, "What is the value of cystoscopy with hydrodistension for interstitial cystitis?", Urology, 66, pp.494~499 (2005)
- Kuo HC, "Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis", painful bladder syndrome, 2009, pp.104, 657~661
- Peeker R, "Complete transurethral resection of ulcers in classic interstitial cystitis", Int Urogynecol J Pelvic Floor Dysfunct, 11, pp.290~295 (2000)
- Hillelsohn JH, "Fulguration for Hunner ulcers : long-term clinical outcomes", J Urol, 188, pp.2238~2241 (2012)
- Niimi A, "Hydrodistension with or without fulguration of hunner lesions for interstitial cystitis : long-term outcomes and prognostic predictors", Neurourol Urodyn, 35, pp.965~969 (2016)
- Ko KJ, "Therapeutic effects of endoscopic ablation in patients with Hunner type interstitial cystitis", BJU Int, 121, pp.659~666 (2018)
- Shao Y, "Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis", Urology, 75, pp.547~550 (2010)
- Hsieh CH, "Hydrodistention plus bladder training versus hydrodistention for the treatment of interstitial cystitis", Taiwan J Obstet Gynecol, 51, pp.591~595 (2012)
- Rawls WF, "Dimethyl sulfoxide(DMSO)as intravesical therapy for interstitial cystitis", bladder pain syndrome : a review, 2017, pp.36, 1677~1684
- Jacob SW, "Dimethyl sulfoxide(DMSO) : a new concept in pharmacotherapy", Curr Ther Res Clin Exp, 6, pp.134~135 (1964)
- Shiga KI, "Dimethyl sulphoxide relaxes rabbit detrusor muscle by decreasing the Ca2+ sensitivity of the contractile apparatus", Br J Pharmacol, 151, pp.1014~1024 (2007)
- Santos NC, "Multidisciplinary utilization of dimethyl sulfoxide : pharmacological, cellular, and molecular aspects", Biochem Pharmacol, 65, pp.1035~1041 (2003)
- Birder LA, "DMSO : effect on bladder afferent neurons and nitric oxide release", J Urol, 158, pp.1989~1995 (1997)
- Wein A, "Interstitial cystitis: an introduction to the problem" (1990), Springer-Verlag
- Ek A, "The use of dimethyl-sulfoxide(DMSO)in the treatment of interstitial cystitis", Scand J Urol Nephrol, 12, pp.129~131 (1978)
- Peeker R, "Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis : a prospective, randomized doubleblind study", J Urol, 164, pp.1912~1915 (2000)
- Tomoe H, "In what type of interstitial cystitis", bladder pain syndrome is DMSO intravesical instillation therapy effective?, 2015, pp.4, 600~604
- Hanno PM, "AUA guideline for the diagnosis and treatment of interstitial cystitis", bladder pain syndrome, 2011, pp.185, 2162~2170
- Hanno PM, "Diagnosis and treatment of interstitial cystitis", bladder pain syndrome : AUA guideline amendment, 2015, pp.193, 1545~1553
- Lee SW, "Transurethral resection alone vs resection combined with therapeutic hydrodistention as treatment for ulcerative interstitial cystitis : initial experience with propensity score matching studies", Urology, 99, pp.62~68 (2017)
- Lee CL, "Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis", bladder pain syndrome, 2015, pp.7, 4283~4293